Using high energy ultrasound beams to destroy prostate cancer tumours may be as effective as surgery or radiotherapy, but with fewer side effects | European Urology | via ScienceDaily
A new study, carried out at six hospitals across the UK, tracked 625 men with prostate cancer who received a type of treatment called high-intensity focused ultrasound (HIFU).
The research, published in the journal European Urology, is the largest ever study of HIFU treatment used to target prostate tumours. The treatment is similar to a ‘lumpectomy’ for other cancers — where doctors remove only tumour cells, leaving as much healthy tissue as possible.
The findings, from a number of institutions including Imperial College London and University College London, found that after five years the cancer survival rate from HIFU was 100 per cent. Approximately, 1 in 10 men needed further treatment. The cancer survival rate from surgery and radiotherapy is also 100 per cent at five years.
The research also showed the risk of side effects of HIFU, such as urinary incontinence and erectile dysfunction, were lower than other treatment options, at 2 per cent and 15 per cent respectively.
A new test which uses saliva to identify men with a high risk of developing prostate cancer has been devised by international researchers led by scientists at the Institute of Cancer Research, London. The DNA test which identifies the 1 per cent who are at highest risk of prostate cancer, and are also six times more likely to develop the disease than the general population. The scientists will now trial the test in 300 patients across three GP practices in London (via The Institute of Cancer Research).
NIHR | April 2018 | Prime minister announces £75 million to support new prostate cancer research
Prostate cancer is the most common cancer in men. It has recently overtaken breast cancer as the third most common cause of cancer deaths in the UK. Now, £75 million funding has been announced by the Prime Minister to support new research into early diagnosis and treatment of prostate cancer. This will be used to complement and extend research undertaken over the past 15 years by the NIHR, Cancer Research UK, Prostate Cancer UK and the Medical Research Council.
New studies will test treatments such as more precise radiotherapy, high-intensity focused ultrasound, and cryotherapy, alongside supportive interventions including exercise and dietary advice.
They will also particularly target groups at higher risk of prostate cancer, such as black men – one in four of whom will develop the disease – men aged 50 or over, and men with a family history of prostate cancer.
Dr Jonathan Sheffield, Chief Executive at the NIHR Clinical Research Network, said:
“Clinical research brings us closer to the development of new treatments for prostate cancer patients.
“The NIHR will work closely with the NHS, life sciences industry, charities and research funders to support the recruitment of 40,000 men into research studies over the next five years. This will provide more opportunities for earlier access to new drugs and therapies, which will ultimately lead to improved diagnoses and care in the future.”
The study included over 400,000 British men aged 50-69. Men were randomized into an RN appointment, where they were offered information on a PSA test, and if they chose, the test. The other group didn’t invite men for testing. After a 10 year period, the study found that there were more prostate cancers detected from this one-time testing. However, this group was no less likely to die from prostate cancer.
Given there was no difference in mortality between the two groups Gavura asks the question as to whether to PSA screen or not?
NHS ‘one stop shop’ for prostate cancer means faster and more accurate diagnosis | NHS England
The NHS is using cutting edge technology to help slash diagnosis times for prostate cancer from six weeks to one day in a world-leading new approach that virtually eliminates the risk of deadly sepsis.
The new scanning and diagnosis method means a ‘one-stop-shop’ for suspected prostate cancer, the most common cancer in men in the UK, with over 40,000 new cases diagnosed every year.
The NHS is determined to cut the mortality rate for prostate cancer in the same way that has seen breast cancer rates decline by 10%.
The usual process is an MRI scan followed by a biopsy where around a dozen samples may have to be taken with a needle through the rectum, in order to locate suspect growths on the prostate.
Under the new ‘rapid pathway’ approach, which is being developed in three hospitals across West London, men have a scan, get their results and can have any necessary biopsy, using new FUSION technology, in one day, rather than multiple outpatient visits over four to six weeks.
Improving the Diagnosis of Prostate Cancer | The University of York Centre for Health Economics
In diagnosing prostate cancer, the objective is to find the men with clinically significant prostate cancer, who are at high risk of metastases and who benefit the most from immediate treatment.
This economic evaluation examines a model which simulates the long-term costs and health consequences of immediate diagnosis and treatment compared with monitoring. By linking the diagnosis outcomes with the long-term costs and consequences, the model evaluates the costs and health consequences of the different diagnosis strategies over the patients’ expected lifetime.